Your cart is empty.
Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.
- Shop
- Blog
-
About
About Tecan
Investors
Press Center
People
Publications
- Support
- Contact
- Life Sciences
- Diagnostics
- Partnering
- Language
The Blog
Selected category: Cancer
Back to overview
Considering mass spec for therapeutic drug monitoring? Here are 4 pitfalls to avoid
By Dr Manuel Bauer
As we saw in part 1 of this blog series, liquid chromatography-tandem mass spectrometry (LC-MS/MS) is potentially the new gold standard for therapeutic monitoring of immunosuppressant drugs (ISD). However, for this technology to become widely adopted, the methodology needs to be standardized globally, including addressing bottlenecks both at the pre-analytical stage of sample preparation, and within the process itself. Here we take a look at the top four pitfalls to avoid when implementing LC-MS/MS for ISD monitoring.